SHP Share Price

Open 4731.00 Change Price %
High 4788.00 1 Day 68.50 1.45
Low 4731.00 1 Week 47.00 0.99
Close 4778.50 1 Month 214.50 4.70
Volume 2002999 1 Year 497.50 11.62
52 Week High 5377.00
52 Week Low 2707.19
SHP Important Levels
Resistance 2 4831.34
Resistance 1 4809.57
Pivot 4765.83
Support 1 4747.44
Support 2 4725.66
LON UK Most Active Stocks
LLOY 72.57 0.57%
FRR 0.28 -12.50%
CWC 74.60 0.27%
CWC 74.60 0.27%
CWC 74.60 0.27%
INC 0.04 -20.00%
NYO 0.08 -20.00%
IRG 0.40 -9.09%
IRG 0.40 -9.09%
IRG 0.40 -9.09%
More..
LON UK Top Gainers Stocks
AKT 28.50 5177.78%
HHR 58.00 900.00%
MLD 10.00 700.00%
MES 0.28 75.00%
MES 0.28 75.00%
MES 0.28 75.00%
PFLM 5.75 64.29%
LDP 0.03 50.00%
LDP 0.03 50.00%
ERE 5.00 25.00%
More..
LON UK Top Losers Stocks
ENDV 0.02 -99.85%
KEA 0.10 -91.30%
ACU 0.05 -87.50%
ACU 0.05 -87.50%
ACU 0.05 -87.50%
DCP 0.50 -75.61%
PCI 3.50 -53.27%
PCI 3.50 -53.27%
BHR 0.02 -33.33%
NBR 0.25 -24.24%
More..

Shire PLC (LON: SHP)

SHP Technical Analysis 3
As on 24th May 2017 SHP Share Price closed @ 4778.50 and we RECOMMEND Buy for LONG-TERM with Stoploss of 4766.14 & Buy for SHORT-TERM with Stoploss of 4695.78 we also expect STOCK to react on Following IMPORTANT LEVELS.
SHP Target for May
1st Target up-side 4730.07
2nd Target up-side 4865.39
3rd Target up-side 5000.71
1st Target down-side 4343.93
2nd Target down-side 4208.61
3rd Target down-side 4073.29
SHP Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.shire.com
SHP Address
SHP
5 Riverwalk
Citywest Business Campus
Dublin, 24
Ireland
Phone: 353 1 429 7700
SHP Latest News
Shire PLC (SHP) Given Outperform Rating at Credit Suisse Group AG   The Cerbat Gem   - 24th May 17
Shire PLC 24.4% Potential Upside Indicated by JP Morgan Cazenove   DirectorsTalk Interviews   - 23rd May 17
Shire and tiny Lexington biotech say hemophilia drug trial misses mark   Boston Business Journal   - 22nd May 17
Shire plc (SHPG) to Offer New Research Into Chronic Hypoparathyroidism at the ...   StreetInsider.com   - 19th May 17
Shire's swelling disorder drug moves closer to US approval   Reuters   - 18th May 17
Shire: Post-Earnings Analysis   Seeking Alpha   - 04th May 17
It's Time To Buy Shire   Seeking Alpha   - 04th May 17
Shire Plc (SHPG) Q1 2017 Results - Earnings Call Transcript   Seeking Alpha   - 02nd May 17
Shire reports better than expected first-quarter results boosted by its ...   Proactive Investors UK   - 02nd May 17
Shire licenses dry-eye treatment for $20 million   Philly.com   - 01st May 17
Interactive Technical Analysis Chart Shire PLC ( SHP LON UK )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Shire PLC
SHP Business Profile
Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; ELVANSE/TYVENSE; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, it offers FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. Further, the company provides REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. Additionally, it offers FOSRENOL for the treatment of hyperphosphatemia in end stage renal disease; XAGRID for the reduction of elevated platelet counts; and CINRYZE, a C1 esterase inhibitor therapy for routine prophylaxis against hereditary angioedema. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. Shire plc markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. The company sells its products in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc has research collaboration with Santaris Pharma A/S. The company was founded in 1986 and is headquartered in Dublin, Ireland.